Featured Research

from universities, journals, and other organizations

Imaging Technology Helps Identify Esophageal Cancer Patients Who Respond Well To Treatment

Date:
March 23, 2006
Source:
Wake Forest University Baptist Medical Center
Summary:
New research at Wake Forest University Baptist Medical Center shows that Positron Emission Tomography (PET) is more accurate than conventional imaging in identifying patients who have good responses to chemotherapy and radiation treatment -- a finding that could one day help some patients avoid surgery.

New research at Wake Forest University Baptist Medical Center shows that Positron Emission Tomography (PET) is more accurate than conventional imaging in identifying patients who have good responses to chemotherapy and radiation treatment -- a finding that could one day help some patients avoid surgery.

The results, from a study of 64 patients with esophageal cancer, are published in the April issue of Annals of Surgery. PET, a technology that produces images of the metabolic function of tissue, was used to test patients for cancer after treatment with a combination of chemotherapy and radiation (chemoradiation).

"While additional multi-center studies are needed, the research clearly shows that PET is a useful tool for identifying patients who respond well to chemoradiation," said Edward A. Levine, M.D., lead investigator. "Being able to identify these responders may alter the need to take some patients to surgery."

Over the past two decades, the most common treatment for esophageal cancer has been chemoradiation followed by surgery. Even with these treatments, the prognosis is poor for most patients, with long-term control rates of 25 to 35 percent. Some patients, however, respond well to chemoradiation and have improved long-term survival.

Identifying which patients will respond to chemoradiation alone -- and perhaps avoid surgery to remove part of the esophagus -- has been difficult. Conventional imaging, including both computed tomography (CT) and endoscopic ultrasound (EUS), are poor predictors of response to chemoradiation.

Recently, PET was shown to be more accurate than CT and EUS in evaluating newly diagnosed patients to determine the extent of the disease. So, Wake Forest researchers decided to evaluate its ability to determine response to chemoradiation.

"The technology has allowed us to evaluate the varying responses to chemoradiation in a cross-section of patients," said Levine, professor of surgery and chief of the Section of Surgical Oncology. "We have identified a subgroup of patients with good long-term control rates and improved long-term survival."

The researchers conducted the study between 2000 and 2004 in patients whose cancer had not spread beyond the esophagus and lymph nodes. Patients had a PET scan both before and after chemoradiation. Then, four to six weeks later, eligible patients had surgery to remove part of the esophagus. The surgical pathology reports from 41 patients were compared to PET results -- and PET was found to be 88 percent accurate at correctly identifying patients without disease.

"These results show the predictive power of pre-treatment PET imaging for identifying patients likely to experience a significant tumor response following a course of pre-operative chemoradiation," said Levine. "The evidence suggests the potential for PET to change clinical practice, perhaps helping some patients avoid surgery."

This study was supported, in part, by a grant from the National Cancer Institute.



Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Imaging Technology Helps Identify Esophageal Cancer Patients Who Respond Well To Treatment." ScienceDaily. ScienceDaily, 23 March 2006. <www.sciencedaily.com/releases/2006/03/060322141344.htm>.
Wake Forest University Baptist Medical Center. (2006, March 23). Imaging Technology Helps Identify Esophageal Cancer Patients Who Respond Well To Treatment. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/03/060322141344.htm
Wake Forest University Baptist Medical Center. "Imaging Technology Helps Identify Esophageal Cancer Patients Who Respond Well To Treatment." ScienceDaily. www.sciencedaily.com/releases/2006/03/060322141344.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins